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Abstract
Inflammatory Bowel Disease – comprised of Crohn’s Disease and Ulcerative Colitis (UC) - is a complex, multi-factorial
inflammatory disorder of the gastrointestinal tract. In this study we have explored the utility of naturally occurring
circulating miRNAs as potential blood-based biomarkers for non-invasive prediction of UC incidences. Whole genome maps
of circulating miRNAs in micro-vesicles, Peripheral Blood Mononuclear Cells and platelets have been constructed from a
cohort of 20 UC patients and 20 normal individuals. Through Significance Analysis of Microarrays, a signature of 31
differentially expressed platelet-derived miRNAs has been identified and biomarker performance estimated through a non-
probabilistic binary linear classification using Support Vector Machines. Through this approach, classifier measurements
reveal a predictive score of 92.8% accuracy, 96.2% specificity and 89.5% sensitivity in distinguishing UC patients from
normal individuals. Additionally, the platelet-derived biomarker signature can be validated at 88% accuracy through qPCR
assays, and a majority of the miRNAs in this panel can be demonstrated to sub-stratify into 4 highly correlated intensity
based clusters. Analysis of predicted targets of these biomarkers reveal an enrichment of pathways associated with
cytoskeleton assembly, transport, membrane permeability and regulation of transcription factors engaged in a variety of
regulatory cascades that are consistent with a cell-mediated immune response model of intestinal inflammation.
Interestingly, comparison of the miRNA biomarker panel and genetic loci implicated in IBD through genome-wide
association studies identifies a physical linkage between hsa-miR-941 and a UC susceptibility loci located on Chr 20. Taken
together, analysis of these expression maps outlines a promising catalog of novel platelet-derived miRNA biomarkers of
clinical utility and provides insight into the potential biological function of these candidates in disease pathogenesis.
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Introduction
Inflammatory Bowel Disease (IBD) represents - a chronic
relapsing disorder of the gastrointestinal (GI) tract affecting over
6.6 million individuals in the US and Europe [1]. A significant risk
factor for colorectal cancer, IBD is stratifiable into two disorders:
Crohn’s Disease (CD) and Ulcerative Colitis (UC) [2]. Both these
subtypes are characterized by inflammation of the digestive tract,
with CD involving widespread inflammation of all layers of the GI
tract while UC is characterized by localized inflammation of the
colon. Current modalities for the diagnosis of both the subtypes
involve a combination of invasive endoscopic procedures and
diverse clinical indices that provide only relative measures of
disease severity and outcome. In the absence of well-established
diagnostic gold standards for IBD, there is a collective interest in
the identification of novel clinical biomarkers that are cost-
effective, afford rapid turnover and provide needed insight into
disease complexity and biology [3,4].
The accessibility of nucleic acids in circulation and their
emerging value in correlating disease burden to clinical outcomes
provides an important paradigm for disease surveillance and
therapeutic management [5]. Described first in 1948 in human
blood [6], extra-cellular nucleic acids exist abundantly as both
DNA and RNA species. Despite enigmatic biological functions,
global characterization of their distributions, size and genomic
origins have established them as discriminating indicators of a
range of tumor associated genomic, epigenetic and transcriptional
change [5,7]. Within the various classes of cell-free circulating
nucleic acids, a significant fraction of the genomic content is
composed of miRNAs [8]. Representing a highly stable and
conserved class of ,22 nt long endogenous non-coding transcripts,
miRNAs represent approximately 1–2% known genes in eukary-
otes [9] and function to negatively regulate gene expression
through base-pairing to target mRNAs [10]. Currently over 1000
mature miRNAs are annotated in the human genome [11,12] with
the potential to post-transcriptionally regulate about 30% of all
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tion encompasses a vast array of cellular and developmental
cascades with an increasing number of miRNAs being correlated
to deregulation of these processes [14]. The oncogenic and tumor
suppressive functions of miRNAs are now well-established with
mechanisms ranging from copy number changes, epigenetic
silencing and modification of transcriptional control of miRNA
loci [15]. Specific examples encompass cancers of both hemato-
poietic and non-hematopoietic origin – thus making this species a
promising and tractable candidate for diagnostic screening [7,8].
Biologically, circulating miRNAs survive the extracellular catalytic
environment through sequestration within sub-cellular particles
such as micro-vesicles and exosomes [7]. Current models for their
functionality involve trafficking through circulation to facilitate
long–range communication between different inter-cellular sites.
A key component of the biology of inflammatory bowel disease
(IBD) involves a deregulated immune response against intra-luminal
bacterial antigens leading to intestinal tissue injury. In recent years,
a collection of expression profilingstudies have provided compelling
evidence for the role of miRNAs in modulating crucial steps of the
immune response [16]. Specific examples include varied roles of
miR-16, miR-17,92 and the miR-146 family in modulating
different aspects of innate and adaptive immunity. Additionally,
evidence from auto-immune disorders such as rheumatoid arthritis,
psoriasis and systemic lupus erythematosus further endorse the
diversity of miRNA functions in various immune cascades [16].
Although the specific role of miRNAs in intestinal diseases are
poorly understood, loss of intestinal miRNAs in mouse models are
known to result in impaired epithelial barrier function resulting in
acuteinflammation[17].Takentogether,thisevidencesuggeststhat
the fundamental physiological role of miRNAs in inflammatory
disorders, such as IBD, is to maintain normal intestinal homeostasis.
Given that the pathology of IBD involves a complex interplay of
immune and non-immune cells, it is of interest to understand the
impact of different classes of blood-derived miRNAs as indicators of
disease physiology [18]. Importantly, platelets, representing an
abundant class of circulating non-immune cells classically engaged
in blood hemostasis are now increasingly recognized as critical
drivers of cell-mediated enteric immune response that lead to the
infiltration of inflammatory cells into the intestinal lumen
[18,19,20]. As a first step towards understanding the contribution
of circulating miRNAs of specific lineages in IBD, we have explored
through microarray analysis, miRNA expression levels in micro-
vesicle, PBMC and platelet fractions from a cohort of 20 normal
and 20 affected individuals diagnosed with Ulcerative Colitis. Using
a Significance Analysis of Microarrays approach [21,22] we can
identify profiles of differentially expressed miRNAs in each fraction.
Furthermore, through a non-probabilistic binary linear classifica-
tion using Support Vector Machines (SVM) [23], we can segment
the dataset to delineate a 31 marker platelet-derived miRNA
signature that has 92.8% accuracy, 96.2% specificity and 89.5%
sensitivity in stratifying UC patients from normal individuals. This
panel can be validated successfully through qPCR assays.
Additionally, correlation analysis of intensity levels across the
patient-control strata reveal subgroups of tightly clustered miRNAs
– suggestive of potential functional relationships through coordinate
regulation of miRNA expression. Taken together, this data suggests
that platelet-derived biomarkers are compelling clinical predictors
of disease outcome; consistent with the emerging role of platelets as
critical players in the pathology of UC. Examination of biological
pathways targeted by these miRNAs reveal enrichment of genes
involved in modulation of cellular architecture and regulatory
cascades implicated in cell-mediated immune response. These
global expression maps thus provide a necessary and critical
resource for biomarker development and begin to provide needed
perspective into the extensive regulatory networks influencing the
clinical expression of this disease.
Results
Biomarker Derivation from circulating miRNA profiles in
different hematological fractions
Given that miRNAs have been shown to reliably classify disease
from normal population and are important mediators in the IBD
mediated inflammatory response, we chose to investigate the
changes in blood-derived miRNA spectrum in a cohort of
Ulcerative Colitis patients. Blood samples from 20 patients and
20 normal individuals, characterized in Table 1 were collected with
informed consent. The case versus control cohorts did not
significantly differ by ethnicity, age, gender or familial cancer
incidences. A statistically significant disposition to Gastrointestinal
(GI) disorders (i.e., Gastritis, IBD, Crohn’s Disease, Colitis) was
found in the patient cohort (8 versus 0 individuals, P=0.0016 by
one-sided Fisher’s Exact Test) while the control patients demon-
strated a greater incidence of non-GI disorders such as diabetes,
coronary diseases, thyroid disorders, hypertension (6 versus 0
individuals, P=0.01 byone-sided Fisher’sExact Test) (Table 1).To
enable identification of inflammation-mediated changes the
samples were specifically sub-fractionated into PBMC (Peripheral
Blood Mononuclear Cells) and platelets. The purity of the isolated
fractions were verified by quantitative PCR amplification of either
the leukocytic mRNA CD45 or platelet specific gene product
Glycoprotein IIB [24] and show a statistically significant and clear
separation of the two fractions (data not shown). Additionally,
micro-vesicular sub-fractions were isolated to identify markers that
were detected free in circulation. Total mRNA from all three sub-
fractions (PBMC, micro-vesicles and platelets) were extracted and
independently profiled on the Affymetrix miRNA arrays contain-
ing 847 human miRNAs. For derivation of miRNA biomarkers
that were differentially expressed (DE) each individual hematopoi-
etic fraction was initially analyzed independently. For each
analysis, the datasets were split 90:10 with 18 individuals randomly
Table 1. Demographics of individuals recruited for this study.
Control Patient
Total 20 20
Ethnicity Caucasian 15/20 (75%) 13/20 (65%)
Others 5/20 (25%) 4/20 (20%)
Unknown none 3/20 (15%)
Gender F 13/20 (65%) 14/20 (70%)
M 7/20 (35%) 6/20 (30%)
Age (yrs) 42.7612.9 49.5611.9
Average age at diagnosis (yrs) N/A 35.5611.9
Family Medical History Cancer 3/20 (15%) 4/20 (20%)
others (non GI) 6/20 (30%) none
others (GI) none 8/20 (40%)
Medical History Cancer 2/20 (10%) none
Ulcerative Colitis none 20/20 (100%)
CD none none
Gender is designated as either M (Male) or F (Female). Disorders are designated
as GI (Gastro-intestinal) or CD (Crohn’s Disease).
doi:10.1371/journal.pone.0031241.t001
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Quantile normalized and processed data from all three fractions
(Fig S1) were analyzed using Significance Analysis of Microarrays
(SAM) and Differentially Expressed (DE) features selected at a False
Discovery Rate (FDR) threshold of 1% (Fig. 1A and Fig S2). A total
of 6, 11 and 52 miRNAs were identified as differentially expressed
from a single iteration of SAM across the PBMC, micro-vesicular
and platelet fractions, respectively (Table S1). We find that the
majority of these signatures to be dominated by profiles of up-
regulated miRNAs, with 92% and 100% of miRNAs demonstrat-
ing increased expression in the platelet and micro-vesicular
fractions, respectively. Interestingly, we find all miRNAs derived
from the PBMC isolates to display down-regulated expression
suggesting distinct biology of each of these isolated miRNA
populations. In order to select miRNAs useful for stratifying
patients from controls, the derivation procedure was repeated 100
times with random re-sampling of the data to minimize the
dependency on a single dataset. Finally, the occurrence of the DE
features obtained from this iterative process was counted and
features demonstrating a frequency no less than 90% selected as
potential biomarkers (Fig. 1A and Fig. 2A). A signature of 31
platelet-derived, 6 microvesicle-derived and 0 PBMC miRNAs
Figure 1. Workflow for biomarker derivation and computation of predictive estimates. (A) Differentially expressed miRNAs were first
derived by SAM and those exhibiting a FDR of ,1% and frequency of occurrence .90% in 100 iterations, were selected as biomarkers. (B) The
decision rules were obtained by SVM classification and the predictive estimates of the selected biomarkers determined by 10-fold cross-validation.
doi:10.1371/journal.pone.0031241.g001
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In order to determine if a combination of the fractions led to a more
discriminative signature the entire derivation process was re-run
using a union of platelet and micro-vesicle fractions. PBMC were
excluded since there were no differentially expressed miRNAs
within that fraction alone. We isolated a list of 29 biomarkers from
this concatenated group and mapped the overlap between the
different lists (Fig. 2B and Fig S2D). We find that 89.6% (26/29)
miRNAs obtained from the combined fraction (derived from
platelet and micro-vesicle) overlap with biomarkers derived from
the platelet fraction only (Fig. 2B, Tables S2 and S4). A subset of
only 6 miRNAs are found to be unique between these two datasets
with hsa-miR-423-3p exclusive to the platelet-micro-vesicle
combined fraction and hsa-let-7i-star, hsa-miR-1271, hsa-miR-
1296, hsa-miR-31 and hsa-miR-345 identified from the platelet
derived fraction only. Additionally, we can also co-identify 33% (2/
6) miRNAs (hsa-miR-202 and hsa-miR-1263) between the
independent micro-vesicle and the micro-vesicle/platelet com-
bined fractions. The remaining set of 4 miRNAs representing 66%
(4/6) of the dataset and comprised of hsa-miR-628-5p, hsa-miR-
603, hsa-miR-221-star and has-miR-455-3p are unique only to the
group of micro-vesicular miRNAs derived from independent
analysis of this fraction (Fig. 2B, Tables S3 and S4). Taken
together, this data characterizes two major signatures of differen-
tially expressed miRNA biomarkers of hematopoetic origins in
Ulcerative Colitis – those that are principally derived from the
platelet fraction and a minority subset of micro-vesicular ancestry.
Development and validation of recurrent miRNA
predictors
To estimate the predictive capability of these signatures, each of
the biomarker categories were subjected to non-probabilistic
binary linear classification using Support Vector Machines
(SVM) (Fig. 1B). Measurement of classifier success was assessed
through a 10-fold cross-validation method. A cohort of randomly
selected 18 case-control subjects were chosen as the training set
while 2 individuals each from the two enrollment categories were
reserved for testing. The training set was further stratified to
randomly sub-select 16 case-control individuals that were subject
to the same feature selection process using SAM, originally used in
biomarker derivation (Fig. 1B). The prediction error rates were
then estimated based on application of the SVM classifier to the
test set (Fig. 2C and Fig S3). Through an iterative cycle of 100
repetitions the performance measures (confusion matrix of true
positives, true negatives, false positives and false negatives) were
computed and recorded for the three principal classes (platelets,
micro-vesicle and their union). The aggregated summary statistics
for these 3 fractions demonstrate that the best classifier
performance is obtained from the 31 miRNAs derived from the
platelet fractions that can classify patient from control individuals
with 92.8% accuracy, 96.2% specificity and 89.5% sensitivity
(Fig. 2C). The platelet and micro-vesicle derived class comprising
of 29 miRNA biomarkers similarly significantly predicted disease
outcome with 92.3% accuracy, 96.8% specificity and 87.8%
sensitivity (Fig. 2C). The performance measures of micro-vesicle
Figure 2. Characteristics and performance measures of biomarkers derived from Platelets, Micro-vesicles or Platelet/Micro-vesicle
combined fraction. (A) Cumulative distribution frequency (CDF) plots of biomarkers derived from the different fractions. The dotted line represents
the 90% cut-off frequency across the study population (B) Counts and overlaps of miRNA biomarkers derived from the platelet, micro-vesicular and
combined fraction (C) Performance measures of biomarkers from each fraction selected at the 90% frequency threshold.
doi:10.1371/journal.pone.0031241.g002
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accuracy, 84.8% specificity and 40.3% sensitivity) (Fig. 2C). None
of these performance estimates were significantly correlated to
independent biometric variables such as age, gender, height or
weight though regression analysis (data not shown). Misclassifica-
tion estimates of the training data by the final classifier reveal that
only 4 diseased individuals in the micro-vesicle derived category
(p14, p15, p18, p21) were anomalously categorized as normal. In
contrast these estimates were much more conservative in the
platelet-derived or platelet-micro-vesicle combined classes with
respectively only 1 (p3) and 0 individuals, being inaccurately
classified, respectively (Fig S4). These categorization and perfor-
mance measures thus indicate that the principal statistical power in
classification of disease versus normal individuals is driven by the
platelet-derived miRNA biomarker class. This category of
biomarkers therefore represents the most discriminating candi-
dates with the best diagnostic potential.
Independent validation of levels of specific circulating
miRNA biomarkers
We next sought to gain an improved understanding of the
biological levels and validity of the platelet-derived biomarker panel
derived from classifier analysis. The differentially expressed profiles
of the 31 platelet-derived miRNAs (Fig. 3 and Fig S5A)
demonstrating the highest predictive performance was analyzed
through unsupervised hierarchical clustering. The expression map
of the 31 candidate miRNAs displayed a clear separation of the
patient versus control groups (Fig. 3) with 3 patients (p3, p19 and
p21) being misclassified by the clustering algorithm. The relatively
higher proportion of misclassified individuals obtained through this
analysis compared to classifier estimates obtained by SVM (3 vs 1
individual) indicate that unsupervised hierarchical clustering does
not separate the samples as well as the SVM algorithm. The
majority of miRNAs in this panel displayed an average log2 signal
intensity magnitude of .6 with only 23% (7/31) target miRNAs
demonstrating lower abundance processed log2 signal intensity ,6
(Fig S5A). Similarly, the major proportion of biomarkers derived
from the platelet and micro-vesicular combined fraction (72% or
21/29 miRNAs) display comparable log2 intensity distributions of 6
or greater. Both the micro-vesicle specific miRNAs in this
biomarker panel are low abundant with an average log2 signal
intensity of 4.8 for hsa-miR-202 and log2 ,=6 for hsa-miR-1263
(Fig S5B). These differences are visualized through unsupervised
hierarchical clustering of the data which also identify misclassifica-
tion of the same 3 individuals (p3, p19 and p21) as was observed in
the group of platelet-derived miRNAs (Fig S6). In order to
Figure 3. Comparison of expression levels of the platelet-derived miRNA biomarkers in the patient and control cohorts.
Unsupervised hierarchical clustering of samples (controls in blue: C1–C20 and patients in red: P2–P21) based on summarized intensity values from the
31 differentially expressed miRNA biomarkers. The log2 intensity values are shown in the Color Key bar scale.
doi:10.1371/journal.pone.0031241.g003
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sub categories of miRNAs from the platelet-derived biomarker
panel for verification by quanititative PCR (qPCR) assays. First, 24
of the 31 marker panel were identified based on 100% representa-
tion in the cross-validation iterations. These were divided into 4
quartiles based on p-values, mean intensity and fold changes. A
union of all of these categories were taken and eight representative
candidate biomarkers (hsa-miR-188-5p, hsa-miR-22, hsa-miR-
422a, hsa-miR-378, hsa-miR-500, hsa-miR-501-5p, hsa-miR-769-
5p, hsa-miR-874), with distributions ranging from marginally below
the mean to the maximum intensity measurable on the array (log2
intensity values ranging from 7.6 to 13.6 for this frequency measure)
were randomly chosen for validation in pooled platelet samples
derived from patient and control cohorts (Fig. 4). Our results
demonstrate that 88% (7/8) of all the differentially expressed
candidates validated successfully and demonstrated a fold change
difference ranging from 1.4–2.04 on comparing patients over
controls (Fig. 4). These estimates match the array estimates with no
significant difference between the two platforms (p-value of 0.6from
paired Student’s t-test). Taken together this data indicates the
capability of the selected biomarker panel to clearly delineate
patient and control samples with a high degree of confidence.
Segregation of biomarker panel into miRNA clusters
In order to examine possible functional relationships amongst
the miRNA members of the platelet biomarker panel, we next
analyzed correlation of expression patterns between the 31
selected species through comparison of log2 intensities across the
patient and control strata. Our results revealed a clear separation
of 90% of the data or 28/31 of the biomarkers into 4 highly
correlated clusters with an average Pearson correlation coefficient
of 0.75 and p-value,3.95E-05 (Fig. 5 and Table S5). For one of
the largest clusters (Cluster 1) (Fig. 5 and Table S5) we can also
additionally identify miRNA candidates that co-cluster based on
genomic location (i.e. hsa-miR-500 and has-miR-501-5p that
reside closely on Chr. X and hsa-miR-27a-star and hsa-miR-150-
star originating from Chr. 19). Co-localization is observed for two
additional candidate miRNAs in Cluster 3 that are processed
products of the same pre-miRNA: hsa-mir-769-5p and hsa-mir-
769-3p; both localized on Chr. 19. Positional concordance is not
observed for any of the remaining markers (Table S5). This
analysis therefore identifies subsets of miRNAs that demonstrate
correlated expression across the samples, with additional chromo-
some-dependent physical association seen for some selected pairs.
Identification of gene pathways associated with miRNA
biomarker signatures
To understand the biological relevance of the diagnostic
signatures we next wanted to determine the spectra and response
of potential mRNAs targets of the identified platelet-derived
biomarkers. To address this, predicted targets of the 31 miRNAs
were first computationally identified through Target Scan 5.0
[13,25,26] and DIANA microT v3.0. No targets could be
identified for the biomarker hsa-miR-92a-star– and hence this
was excluded from the analysis. A total of 5493 conserved targets
were identified through this process (Table S6) and a subset of
3304 non-redundant mRNA targets of 30/31 biomarkers were
selected and subjected to Gene Ontology (GO) or Ariadne
Ontology and pathway classification using Pathway Studio
software. Biologically relevant groups were identified by analyzing
for significant shared ontology terms. Our analysis revealed that
the biomarker targets were significantly enriched in genes
associated with transcriptional categories such as transcription
factor activity, regulation of transcription nucleotide binding and
actin-based cytoskeleton assembly (p-value,1.33610
28) implying
a biological role of these miRNAs in the regulation of these
processes (Table 2 and Table S7). Significantly, we find
approximately 27% of the regulated targets (526 genes) to be
involved in the regulation of transcription, 32% (65 genes)
participating in actin-based cytoskeleton assembly and between
9–14% (15–54) of genes engaged in diverse lipid metabolism
pathways (Table 2 and Table S7). Additionally, through the
analysis of annotated signaling pathways we also find enrichment
of signaling pathways that participate in both cytoskeleton
regulation and immune-mediated inflammatory response. Specif-
ically we observe between 24–58% overlap of miRNA targets with
Figure 4. Validation of expression levels of miRNA biomarkers derived from the platelet fraction. miRNA expression levels of 7
biomarkers (n=4, *P values,0.001) were validated by qPCR. The p values are calculated based on a Student’s t-test of the replicate 2‘ (2DCt) values
for each miRNA in the control group (normal individuals) and test groups (patients).
doi:10.1371/journal.pone.0031241.g004
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known to be involved in triggering the innate immune response
(Table 2 and Table S7). Taken together this data indicates that
genic targets of diagnostic miRNA biomarkers of Ulcerative Colitis
are selectively enriched in candidate genes that engage in aspects
of the pro-inflammatory response observed in the pathophysiology
of this disease.
Discussion
Diagnostic assessment and therapeutic management of IBD
spectrum disorders currently derives from a combination of
clinical examination, laboratory indices and invasive procedures
[27]. Given the emerging association of circulating miRNA species
with a spectrum of physiological and disease conditions [7] we
have systematically explored the utility of secretory miRNAs
isolated from different hematological fractions as non-invasive
predictors of Ulcerative Colitis.
To address this question, we have investigated broadly across
distinct whole blood fractions comprising both cellular (platelets,
PBMC) and acellular compartments (exosomal/micro-vesicular)
that are known to express and shuttle miRNA cargo through
circulation. A set of distinct, differentially expressed maps of
annotated miRNAs have been constructed from a cohort of 20
diseased versus 20 normal individuals through hybridization to
miRNA arrays. Fraction-specific differentially expressed miRNA
signatures have been interrogated through SAM [21] at a 1%
FDR [22] that identify primarily up-regulated miRNA candidates
in the full dataset with only a minority of miRNAs displaying
down-regulation of expression. Through molecular classifiers
derived from a Support Vector Machine model and a multiple
random sub-sampling strategy, our results (Fig. 2C) have isolated a
distinct diagnostic signature of 31 miRNAs with increased
expression that derive specifically from the platelet fraction and
can stratify UC patients from normal individuals with 92.8%
accuracy, 96.2% specificity and 89.5% sensitivity. Given the low
number of differentially expressed miRNAs from the PBMC and
micro-vesicular fractions, no predictive miRNA species could be
identified from the PBMC isolates and only a poorly performing
minority 6-marker panel derived from independent analysis of the
Figure 5. Sub-clusters of platelet-derived miRNA biomarkers. Unsupervised hierarchical clustering of miRNA biomarkers based on the
Pearson correlation coefficients among the miRNA expression profiles from 20 patients and 20 controls. The coefficient values are shown in the bar
scale. Each of the 4 main clusters with significant correlation values are indicated in boxes.
doi:10.1371/journal.pone.0031241.g005
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obtained from combination of the platelet and micro-vesicular
strata which generate a 29 marker panel consisting 27 platelet-
derived and 2 micro-vesicular markers with comparative predic-
tive performance in distinguishing case from control (92.3%
accuracy, 96.8% specificity and 87.8% sensitivity). Given the
significant overlap observed between the platelet-derived and
platelet+micro-vesicle-derived profiles (Fig. 2B) and the poor
performance metrics of the non-platelet miRNAs we conclude that
the origin of the majority of disease-specific predictors in UC map
back to the anucleate platelet fraction. Additionally, since classifier
analysis did not identify any down- regulated miRNA biomarkers,
this data also suggests that the primary physiological response in
Ulcerative Colitis is to enhance expression of miRNA subsets. The
divergence of platelet vs. micro-vesicular signatures is interesting
and indicates distinct sub-cellular addresses for these miRNA
species. Taken together, this supports the hypotheses that the
isolated micro-vesicle fraction mapped in this study either do not
Table 2. Gene ontology (GO) classification and pathway analysis of predicted mRNA targets of the 31 platelet-derived biomarkers.
Annotation Term
Genome
annotation Overlap
# % Overlap p-value
Actin-based cytoskeleton assembly Ariadne Ontology 202 65 32 2.74E-10
Transcription factors 955 203 21 1.33E-08
Vesicular secretory pathway 93 33 35 5.69E-07
TGFBR 16 9 56 0.000143
Regulation of transcription Biological Process 1937 526 27 2.41E-125
Transcription 2282 517 22 5.18E-90
Nucleotide binding Molecular Function 2265 462 20 1.50E-43
Transcription factor activity 1215 297 24 1.53E-42
DNA binding 2430 476 19 4.89E-40
Kinase activity 783 207 26 1.09E-34
Transferase activity 1547 325 21 1.40E-32
Actin binding 375 86 22 2.18E-11
Actin Cytoskeleton Regulation Signaling Pathways 548 176 32 3.10E-16
NTRKRAP-1/CREB/ELK-SRF/MYC/SMAD3/TP53 95 45 47 7.75E-11
Gonadotrope Cell Activation 722 197 27 2.24E-10
FGFRRAP-1/CREB/CREBBP/ELK-SRF/MYC 98 44 44 1.09E-09
EGFRRAP-1/CREB/ELK-SRF/MYC 93 42 45 2.11E-09
ThrombopoietinRRAP-1/CREB/ELK-SRF/MYC 85 39 45 4.57E-09
ThrombinRRAP-1/CREB/ELK-SRF/SP1 110 46 41 7.58E-09
VEGFRRAP-1/CREB/MYC 87 39 44 1.03E-08
FibronectinRRAP-1/ELK-SRF/SREBF 104 44 42 1.05E-08
EphrinRRactin 216 74 34 1.12E-08
PDGFRRAP-1/MYC 77 35 45 3.83E-08
EGFR/ERBB3RMEF/MYOD/NFATC/MYOG 130 50 38 4.63E-08
Focal Adhesion Regulation 322 98 30 5.07E-08
EGFRRAP-1/ATF2 82 36 43 7.40E-08
TNFRSF1ARAP-1/ATF/TP53 36 21 58 1.01E-07
T Cell Activation 951 233 24 1.78E-07
EGFR/ERBB2RTP53 81 35 43 1.82E-07
IGF1RRMEF/MYOD/MYOG 62 29 46 2.65E-07
VasopressinR2RMEF/MYOD/NFATC/MYOG 123 46 37 4.20E-07
ErythropoietinRRAP-1/CREB/MYC 80 34 42 4.39E-07
VasopressinR2RCREB/ELK-SRF/AP-1/EGR 128 47 36 5.88E-07
Glycerophospholipids and ether lipids metabolism Metabolic Pathways 372 54 14 2.65E-09
Sphingolipid metabolism 206 25 12 0.001593
Metabolism of triacylglycerols 103 15 14 0.002504
Glycosylphosphatidylinositol-anchor biosynthesis 136 18 13 0.002855
Pterine biosynthesis 227 22 9 0.038294
Overlap
# refers to the number of gene annotations intersecting with genome annotations. The top ranking GO terms, % overlaps and the counts of overlapping entities
ranked by the most significant p-values are listed.
doi:10.1371/journal.pone.0031241.t002
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derived miRNA cargo into classes destined for trafficking through
the hematopoietic circuit. Given the significant overlaps observed
in previous studies between platelet and micro-vesicular signatures
[28], this disparity may be indicative of disease specific
characteristics of Ulcerative Colitis. The validity of the identified
platelet-derived class can be additionally verified with 88% success
through qPCR assays run on pooled patient and control samples
(Fig. 4) – thus providing independent confirmation of the
differential regulation of this panel. Furthermore, these markers
segregate into 4 highly correlated intensity clusters, often
containing specific pairs of miRNAs that share proximity of sub-
chromosomal location (Table S5). Cumulatively these results
suggest distinct sets of biomarkers that may be coordinately
regulated or share functional regulatory sub-networks closely
synchronized under the given physiological conditions.
The biology of IBD spectrum disorder is known to encompass a
complex interplay of innate and adaptive immunity that ultimately
regulates a regional intestinal inflammation response [29].
Circulating blood platelets representing non-immune cells and
engaged classically in the hemostatic function of surveying vessel
integrity are emergent mediators of active inflammation modulat-
ing local intestinal tissue injury [19,20]. Enriched in a small but
diverse transcriptome [30], platelets contain a large proportion of
mature miRNA that can potentially engage in the regulation of
gene expression. In order to understand the diversity of our
identified miRNA biomarker panel, we have assessed the overlap
between our maps and miRNA profiles from normal or disease-
specific signatures surveyed across different studies. These analyses
identify between 6% (2/31) to 29% (9/31) overlap between the 31-
platelet-derived biomarker panel with miRNAs derived from
platelet populations of normal individuals [24,28,31] and no
overlap with UC specific miRNAs profiled from peripheral blood
[32]. Additionally comparison to miRNA maps of non-platelet
origin involved in a broad spectrum of inflammatory disorders
[16] reveal only two overlapping miRNAs: hsa-miR-140 and hsa-
miR-146b with the majority of the 31 marker panel thus being
exclusive to our study. Taken together, these comparative analyses
clearly delineate that members of the platelet-derived 31
biomarkers are (a) enriched in miRNA species that are typically
not detected in the normal platelet transcriptome, (b) are highly
compartment specific and detectable only on enrichment of the
platelet fraction and (c) display specificity of expression restricted
to Ulcerative Colitis compared to other inflammatory disorders.
Given that miRNAs are known to be collective regulators of
approximately 30% of human genes [13] understanding of the
mechanism of gene regulation mediated through the 31-miRNA
biomarker panel is of importance. The prevalence of biological
functional processes was evaluated through analysis of GO terms
on 3304 non-redundant predicted mRNA targets representing
approximately 13% of the estimated number of protein coding
genes in the human genome [33]. Stratification of the top
canonical groups and pathways reveal enrichment of genes
engaged in actin-cytoskeleton assembly, vesicular secretary
pathway, biosynthesis and metabolism of diverse lipids such as
glycerol phospholipds, pterin and tri-acylglycerol, implicated in a
variety of cell-regulatory and immune stimulation roles (Table 2).
Specific examples include (a) regulation of the members of the
Rho-ROCK pathway involved in cytoskeletal reorganization/cell
adhesion response to wound healing ([34] and references therein),
(b) involvement of sphingolipids as modulators of growth factor
receptors and second messengers of known agonists of the
inflammatory response such as tumor necrosis factor-a, interleu-
kin-1b [35], (c) regulation of Pterin metabolism- in response to
IFN-c stimulation [36], (d) genes involved in ionic transport and
regulation of calcium homeostasis that may influence membrane
permeability and (e) modulators of classic inflammatory regulators
such as TNF-a. The predicted mRNA target spectrum is also
dominated by transcription factors/mediators such as PI3K,
KLF5, etc. that we hypothesize play a role in modulation of key
genes involved in the regulation of the other diverse functions of
metabolism, biosynthesis, transport, etc. [37]. Additionally, we also
find that a subset of the biomarkers (i.e., hsa-miR-1271, hsa-miR-
874, hsa-let-7i-star and hsa-miR-20b-star) can target ATGs16L, a
gene necessary for autophagy and implicated in IBD susceptibility
[38,39]. Therefore, comparison of these targets to published
studies [34,37,40,41] reveal a high degree of concordance in
functional groups but often limited overlaps in terms of specific
gene targets – suggesting that the landscape of physiologically
relevant mRNAs in IBD is far from being saturated. Therefore,
this study complements our current understanding of the UC
transcriptome and provides interesting insight into the expression
divergence of this disorder.
In principal, the platelet derived miRNAs could contribute to
the pathophysiology of UC through regulation of the platelet
transcriptome, consequently influencing downstream interaction
with the intestinal mucosa. Adhesion of platelets to the mucosal
endothelium is known to occur though a CD40/CD40L contact-
dependent process resulting in platelet activation [19,20] and a
chemokine mediated immune response. The ultimate outcome of
this trigger is the recruitment of leucocytes to the endothelium
which results in a focal inflammatory response. These mechanisms
are consistent with the functional classes of mRNA target genes
identified in this study and implicated in the modulation of cellular
architecture and inflammation. Taken together, these results
support a hypothesis which offers a direct role for miRNAs in
influencing platelet activation and cell-cell mediated immune
response in gut inflammation.
Given that micro-vesicles are known mediators of cell-cell
communication [42] it is intriguing to speculate if the miRNA
content of platelets can potentially be transferred to endothelial
cells through vesicular fusion. In this model, the epithelial
transcriptome would be directly targeted by the identified platelet
miRNA regulators. Analysis of differentially expressed miRNA
profiles from colonic epithelial tissues from UC patients can isolate
34% (30 out of 89) significantly down-regulated mRNAs [37]
corresponding to representative targets of 57% (17 out of 30)
miRNAs from our biomarker panel. Comparison of fold change
densities of these anti-correlated target mRNAs against all down-
regulated transcripts on the array, reveal a statistically significant
difference (p-value of 0.011 by Binomial test and 0.007 by Fisher
Exact Test) between the two groups (Fig S7). This suggests that the
platelet miRNAs could possibly be a significant factor in the down-
regulation of endothelial gene expression in the context of IBD.
Given the prevalence and increasing disease-specific role of
miRNAs, it is of interest to catalogue the association of these
sequences with naturally occurring polymorphisms in polygenic
disorders [43]. Mechanistically, single nucleotide changes can have
significant functional impact through either impeding miRNA
biogenesis, or through inhibition of binding to target miRNA
sequences. Examples of such functional polymorphisms are
numerous [44] (http://www.patrocles.org/Patrocles_miRNAs.
htm) and has been demonstrated to impact a variety of disease
states [45,46,47,48]. We can map polymorphisms in the mature
miRNA sequence of 35% of the miRNAs (11 of 31) in our
biomarker signature and 20% (673 out of 3304) of their
computationally predicted mRNA targets (http://compbio.uthsc.
edu/miRSNP/). It is intriguing to speculate whether the patient
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impacted by this type of variation. A link between polymorphisms
and miRNAs were also explored by examining possible associa-
tions of the 31-biomarker prognostic panel with IBD susceptibility
loci identified through genome-wide association studies. We can
identify a close physical link (220 Kb) between hsa-miR-941 and
rs2297441, a SNP mapping to the 20q telomere that is associated
with high confidence to UC [49]. As more evidence demonstrating
the significance of polymorphisms affecting miRNA synthesis,
binding, stability or functional activity accumulates, it will become
important to investigate these changes in the context of disease
associations and diagnostic accuracy of miRNA biomarkers.
The abundance and stability of miRNAs in circulation holds the
promise of easy and rapidly accessible biomarkers. Given the
prognostic and diagnostic utility of this class in cancer and the
inherently vast regulatory potential of miRNA molecules, we have
assessed the ability of fraction-specific miRNAs in delineating
incidencesofUlcerativeColitis.Toourknowledgethecurrentresults
outline for the first time platelet-specific miRNA signatures for an
inflammatory disorder, with exceedingly high predictive measures.
The potential of these biomarkers to influence gene expression in
context of modulating intestinal homeostasis is explored and the
spectrum of putative physiological targets evaluated for their
regulatory potential. In summary, results obtained from this study
support a model where expression and coordinate control of various
polygenic components of UC pathogenesis may be mediated by the
interplay of circulating miRNA species and their physiological
targets. As universally applicable tests are developed a combinatorial
use of these indicators would perhaps provide the most rational
strategy for disease determination and clinical therapy.
Materials and Methods
Ethics statement
The study cohort consisted of 20 anonymized patients recruited
from the office of Main Line Gastroenterology. Additionally, 20
normal samples were obtained from the volunteer staff of the
Lankanau Institute of Medical Research and Lankenau Hospital.
Written informed consent was obtained from all patients prior to
obtaining samples and medical history. The Main Line Hospital’s
Institutional Review Board approved of this study.
Fractionation of whole blood into Micro-vesicle, PBMC
and Platelet fractions and isolation of RNA
Whole blood (7 to 9 ml) was collected from patient and control
individuals in BECTON-DICKINSON 166100 mm 10.0 mL
BD VacutainerH plastic EDTA blood collection Tubes (Becton &
Dickinson, Franklin Lakes, NJ). To protect against RNA
degradation samples were treated with Baker’s yeast RNA (Sigma
R6750) within 5 minutes of draw to give a final concentration of
1.25 mg/ml and then diluted with equal volume of PBS. Samples
were separated into the different hematopoietic fractions by
density gradient centrifugation. Briefly, the diluted blood samples
were layered over Ficoll-Paque
TM plus (GE Healthcare) at a 3:4
ratio by volume and centrifuged at 400 g for 30 to 40 minutes at
25uC. This process resulted in a fractionation of the sample into
plasma (upper layer), PBMCs and platelets (narrow central band),
and a band of erythrocytes and granulocytes at the bottom of the
tube. The upper plasma layer was removed, centrifuged at
100,000 g for 1 hr at 4uC using a Beckman Ti50 rotor and the
pellet isolated to generate the micro-vesicular fraction. This
fraction consists of microparticles, exosomes, and other cellular
debris. To fractionate the PBMC from Platelets, the Ficoll-Paque
layer containing these cellular populations was removed, and 3
volumes of 16PBS added to the layer and the mixture centrifuged
at 65 g for 15 min at room temperature. The supernatant fraction
was saved and the pellet re-suspended in 10 ml PBS and re-
centrifuged under the same conditions. The resulting pellet was
isolated to represent the high density PBMC population. The
supernatant fractions from the first and second washes were
pooled and centrifuged at 450 g for 20 min at room temperature
to isolate the pellet representing the platelet fraction. All three
pellet fractions were mixed with 1 ml of Trizol-LS reagent and
total RNA extracted according to the Trizol procedure.
Labeling and hybridization of platelet, micro-vesicle and
PBMC samples to the Affymetrix miRNA Arrays
Total RNA ranging in concentration from 1 ug–3 ug was
labeled using the Genisphere HSR labeling kit (P/N HSR30FTA)
and hybridized overnight to the Affymetrix Genechip miRNA
array (P/N 901326). The arrays were washed and stained using
standard Affymetrix protocols and scanned using the Affymetrix
GCS 3000 7G Scanner. Feature intensities were extracted using
the miRNA_1-0_2xgain library files.
Quantitative RT-PCR
Assays to quantify differential expression of miRNAs in patients
vs. healthy controls were performed using the ABI 7300 real-time
PCR instrument and miScript quantitative PCR System (Qiagen).
Pooled Patient (P2–P21) and Control (C1–C18 and C20) samples
were used in duplicate Reverse Transcription (RT) reactions.
Approximately 10 ng of cDNA was used in duplicate PCR assays
for each RT. The normalizers used for this analysis were:
Hs_RNU6B_3, Hs_miR-320b_2, Hs_miR-543_1and Hs_miR-
654-3p_2. For analysis of the purity of the platelet fraction, patient
and control pools from each of the plasma-derived classes of platelets
and PBMCs were similarly tested using 66.6 ng of total RNA and
QuantiFast
TM SYBRH Green RT-PCR system (Qiagen). The
platelet specific gene ITGA2B (Glycoprotein IIB) and the leukocyte
specific CD45-common antigen marker PTPRC were used as target
mRNAs and 18S (RRN18S) and Actin (ACTB) used as normalizers.
All oligonucleotide sets were purchased from Qiagen.
Datasets
The datasets described in this manuscript are MIAME
compliant and have been deposited in NCBI’s Gene Expression
Omnibus Database (http://www.ncbi.nlm.nih.gov/geo/).
The data series is accessible through GEO Series accession
number GSE32273:http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE32273.
Analysis of the miRNA data
Data Preprocessing: Data preprocessing was performed via
Affymetrix miRNA QC Tool, which consisted of extraction of raw
intensities for each individual feature followed by background
subtraction based on GC content of anti-genomic probes,
transformation of values through addition of a small constant
(value 16), quantile normalization and finally median summariza-
tion of all probe sets for each feature. The intensity data used in all
analysis are log2 transformed. Triplicates available for one case
(p7) and one control (c9) for each of the fractions under study were
analyzed by utilizing the mean intensity values.
Software Packages: All statistical analysis was performed
under the R programming language environment (www.r-project.
org). The R ‘‘samr’’ package was used for Significance Analysis for
Microarray (SAM) and the R ‘‘e1071’’ package was used for
Support Vector Machine (SVM) with the non-linear radial basis
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algorithm was implemented in the R ‘‘hclust’’ function and
generated using Euclidean distance matrix and complete-linkage
agglomeration. All heat maps were generated using the R ‘‘gplots’’
package.
miRNA Biomarker Selection: Biomarker selection was
based on 100 iterative cycles of SAM run on re-sampling of the full
20 patient and 20 control sample set through a randomized 9:1
data split (i.e., a ‘training set’ of 18 cases and 18 control individuals
per iteration). Each individual fraction (platelet, micro-vesicle or
PBMCs), or the combination of all three fractions were separately
analyzed. Differentially expressed (DE) miRNA features were
identified at a False Discovery Rate of 1% and features occurring
at a frequency greater than 90% (consensus features) selected as
potential biomarkers.
Cross-Validation to Estimate Prediction Error Rates:
Support Vector Machines (SVM) was used for classifying the IBD
cases from controls. To assess the prediction error rates a 10-fold
cross-validation procedure was applied (Fig. 1). Briefly, the full
data set of 20 cases/controls was randomly sampled to generate a
training set of 18 cases/controls and a testing set of 2 cases/
controls. The training set was further split into a random subset of
16 cases/controls and the biomarker derivation process run
iteratively through SAM to select the consensus features followed
by SVM classification. The decision function obtained by SVM
classification was applied to the testing set and the confusion
matrix (e.g., counts of false positives and false negatives) recorded.
The entire procedure was repeated 100 times and the prediction
error rates estimated from the aggregated confusion matrix.
Inter-feature correlation analysis among the 31 Bio-
markers: The correlation structure among the 31 platelet-
derived biomarkers was examined by calculating the Pearson’s
correlation coefficients among the 31 miRNAs based on their
normalized expression profiles across all cases and control
individuals. Clusters were defined as subgroups exhibiting minimal
correlation coefficients .0.6 and were identified by visualizing the
heat map plotted by unsupervised hierarchical clustering.
Prediction of miRNA targets and enrichment analysis:
For prediction of mRNA targets, the 31 platelet derived biomarkers
were first separated into two categories based on the star
designation. Targets were determined using either DIANA-microT
3.0 algorithm for the star miRNA sequences (http://diana.cslab.
ece.ntua.gr/) or TargetScan Human v5.0 (http://www.targetscan.
org/cgi-bin/targetscan/data_download.cgi?db=vert_50) for the
non-star miRNA sequences. Targets were selected based on
conservation of families/sites from Target Scan and a precision
score greater than 0.4 from DIANA. A total of 5493 mRNA targets
were identified out of which 3304 unique mRNAs were selected
after removing redundancies and subjected to pathway exploration
using Pathway Studio software from Ariadne Genomics (http://
www.ariadnegenomics.com/). Using this software and its accom-
panying Gene Ontology and Interaction databases, incidence of
predictedmiRNAtargetswerematchedagainst thetarget collection
and the top-ranking pathways and Gene Ontology groups selected.
The statistical enrichment for each of these pathways/groups was
computed by the similarity score or p-value calculated as a ratio of a
number of common objects between two pathways to the total
number of objects in them.
Correlation Analysis of miRNA and mRNA Expres-
sions: To identify expression changes in putative target tissue
mRNAs, genome–wide mRNA expression data from colonic
pinch biopsies of Ulcerative Colitis patients were analyzed [37].
The pre-processed raw intensities for 12,258 probes (excluding the
control probes from the array) were extracted from patient-control
cohorts (4 normal individuals and 5 affected Ulcerative Colitis
patients). Differentially expressed mRNAs were identified by SAM
at an FDR ,0.1% and genes exhibiting a fold change .2 selected
for further analysis. The numbers of differentially expressed genes
were counted for both the whole array and the miRNA targets and
enrichment of down-regulated target mRNAs assessed by either
the Binomial test or the Fisher’s Exact test. The null hypothesis for
this analysis tests that the proportion of down-regulated miRNA
target genes is equivalent to the fraction of down-regulated genes
predicted not to be miRNA targets. The alternative hypothesis
tests that the proportion of down-regulated miRNA target genes is
larger than the non-target miRNA genes.
Supporting Information
Figure S1 Box plot of log2 signal intensity distribution
of human miRNAs (white) and background probes (red)
for 20 patients and 20 controls for each fraction (A)
Platelets (B) Micro-vesicles (C) PBMC after background
subtraction, quantile normalization and median sum-
marization. The black bar represents the median of each
distribution and the dashed lines represent the box–plot range set
by the whiskers.
(TIF)
Figure S2 Analysis of differentially expressed miRNA
biomarkers from (A) Platelets (B) PBMC (C) Micro-
vesicular and (D) Combined Platelet and Micro-vesicle
fractions. Comparison of observed vs. the expected scores
obtained by performing Significance analysis of microarrays on all
847 miRNAs from 20 patients and 20 controls. Each miRNA is
represented by a point (open circle), and the differentially
expressed miRNAs represented as red (for up-regulated) or green
(for down-regulated) points in the graph. The dashed line
represents a FDR threshold of 1%.
(TIF)
Figure S3 Performance estimates for the different
fractions isolated in this study at a frequency cutoff of
90%. The Combined fraction denoted by asterisk is representa-
tive of the union of all the 3 different fractions of PBMC, micro-
vesicles and platelets. The different error rate calculations are
given by FPR (False Positive Rate), FNR (False Negative Rate),
PPV (Positive Prediction Value) and NPV (Negative Prediction
Value).
(TIF)
Figure S4 Table of predicted and observed values from
each analyzed fraction based on Confusion Matrix
derived from SVM on the full data comprising 20 cases
and 20 controls.
(TIF)
Figure S5 miRNA expression levels in patient and
control cohorts. (A) Box plot of processed log2 intensity
distributions of 31 miRNA biomarkers from Platelet fraction or
(B) 29 miRNAs from the Platelet/Micro-vesicle combined fraction.
The black bar represents the median of each distribution and the
dashed lines the box-plot ranges. The open circles represent the
outliers. The patient samples are denoted by red (cases) and
normal samples by blue (controls). The platelet-derived miRNAs
are denoted with the prefix ‘pl’ and the micro-vesicular miRNAs
are designated as ‘mv’.
(TIF)
Figure S6 Comparison of expression levels of miRNAs
biomarkers in the patient and control cohorts derived
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fractions. Unsupervised hierarchical clustering of samples
(controls in blue: C1–C20 and patients in red: P2–P21) based on
processed log2 intensity values from 29 biomarkers. The log2
intensity values are shown in the Color Key bar scale. The
platelet-derived miRNAs are denoted with the prefix ‘pl’ and the
micro-vesicular miRNAs are designated as ‘mv’.
(TIF)
Figure S7 Correlation of platelet-derived miRNA and
mRNA targets. Relationship between the fold change densities
of miRNA targets and all transcripts measured from expression
profiling of endothelial pinch biopsies from UC vs normal
individuals. The p-values denote significant differences in the
population of down-regulated genes between miRNA targets and
all transcripts by either Bionomial test (*) or by Fisher’s Exact Test
(**).
(TIF)
Table S1 Lists of differentially expressed miRNAs
identified by SAM from the entire dataset of platelets,
PBMC and micro-vesicular fractions at an FDR of 1%.
The ‘‘Score’’ represents the modified t-test statistics calculated by
SAM. The ‘‘Fold Change’’ denotes the ratios of the mean intensity
in patient samples over control samples. The q-value represents an
estimate of FDR. This number is typically greater than 0. In our
dataset due to the limiting sample size (20 cases and 20 controls)
we observe for some features the test statistic to be more extreme
than all observed in permutations. Therefore the estimated FDR for
declaring that feature to be significant is set to 0.
(XLSX)
Table S2 List of 31 biomarkers derived from the
platelet fraction.
(XLSX)
Table S3 List of 6 biomarkers derived from the micro-
vesicle fractions.
(XLSX)
Table S4 List of 29 biomarkers derived from a combi-
nation of platelets and micro-vesicular fraction.
(XLSX)
Table S5 List of 4 principle miRNA clusters derived
from the platelet biomarker panel showing correlated
expression profiles and genomic coordinates of the
miRNAs.
(XLS)
Table S6 List of predicted mRNA targets of the 31
biomarkers identified by TargetScan and DIANA.
(XLS)
Table S7 List of enriched GO and Pathway analysis
terms and mRNA targets in each significant category.
The percentage of overlap and the overlapping entities of the top
groups/pathways ranked by the most significant p-values are
shown.
(XLS)
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